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Abstract
Chronic silent brain infarctions, detected as new white matter hyperintensities on magnetic resonance imaging (MRI) fol-
lowing transcatheter aortic valve implantation (TAVI), are associated with long-term cognitive deterioration. This is the first 
study to investigate to which extent the calcification volume of the native aortic valve (AV) measured with cardiac computed 
tomography angiography (CTA) predicts the increase in chronic white matter hyperintensity volume after TAVI. A total of 
36 patients (79 ± 5 years, median EuroSCORE II 1.9%,  Q1–Q3 1.5–3.4%) with severe AV stenosis underwent fluid attenu-
ation inversion recovery (FLAIR) MRI < 24 h prior to TAVI and at 3 months follow-up for assessment of cerebral white 
matter hyperintensity volume (mL). Calcification volumes  (mm3) of the AV, aortic arch, landing zone and left ventricle were 
measured on the CTA pre-TAVI. The largest calcification volumes were found in the AV (median 692 mm3) and aortic arch 
(median 633 mm3), with a large variation between patients  (Q1–Q3 482–1297 mm3 and 213–1727 mm3, respectively). The 
white matter hyperintensity volume increased in 72% of the patients. In these patients the median volume increase was of 
1.1 mL  (Q1–Q3 0.3–4.6 mL), corresponding with a 27% increase from baseline  (Q1–Q3 7–104%). The calcification volume 
in the AV predicted the increase of white matter hyperintensity volume (Δ%), with a 35% increase of white matter hyper-
intensity volume, per 100 mm3 of AV calcification volume (SE 8.5, p < 0.001). The calcification volumes in the aortic arch, 
landing zone and left ventricle were not associated with the increase in white matter hyperintensity volume. In 72% of the 
patients new chronic white matter hyperintensities developed 3 months after TAVI, with a median increase of 27%. A higher 
calcification volume in the AV was associated with a larger increase in the white matter hyperintensity volume. These findings 
show the potential for automated AV calcium screening as an imaging biomarker to predict chronic silent brain infarctions.
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Background
Transcatheter aortic valve implantation (TAVI) has been estab-
lished as an effective treatment of severe aortic valve (AV) 
stenosis, reducing both clinical symptoms and mortality. Nev-
ertheless, one of the most feared complications, namely the 
occurrence of stroke, is still observed in 2.4% of the patients 
undergoing TAVI [1]. This complication is observed despite 
the expansion to low-risk populations, the increase in operator 
experience and the development of improved valve-systems 
[2]. The cerebral emboli during TAVI are attributed to the 
dislodgement of aortic arch calcifications during the advance-
ment of the catheter through the orifice and the expansion of 
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the implanted valve crushing the calcified native valve [3]. Our 
previous research showed that stroke after TAVI is associated 
with poor outcomes, including a sixfold increase of procedural 
mortality [1]. Nevertheless, clinically overt strokes are only 
the tip of the iceberg, since shortly after TAVI acute silent cer-
ebral infarctions are visible with diffusion-weighted magnetic 
resonance imaging (DW-MRI) in up to 78% of the patients 
[4]. Unfortunately, currently the majority of the TAVI-induced 
cerebral emboli remains unpredictable.
Cardiac computed tomography angiography (CTA) scans 
are part of the routine pre-TAVI work-up and may be used 
to measure the local calcification burden in the area of the 
AV and arch [5]. This is confirmed by a previous study that 
showed that a large plaque volume in the AV prior to TAVI 
predicted the occurrence of acute silent brain infarctions sev-
eral days after TAVI [6]. Despite a high increase of acute 
silent brain infarctions, these lesions have as yet not been 
related to long-term cognitive deterioration [7]. Previous 
research showed that only a proportion of the acute silent 
brain infarctions, as detected with DW-MRI several days 
after TAVI, proceeded into chronic loco-regional remnants, 
which can be identified as white matter hyperintensities on 
fluid attenuation inversion recovery (FLAIR) MRI sequence, 
several months after TAVI [7].
In contrast to acute silent brain infarctions, chronic white 
matter hyperintensities that emerged after the procedural 
phase were associated with a decrease in cognitive func-
tioning during long-term follow-up [7]. Moreover, in the 
general elderly population white matter hyperintensities are 
associated with cognitive impairment, a twofold higher risk 
of dementia and a threefold higher risk of stroke [8]. TAVI 
has been developed to improve quality of life, however the 
increase in TAVI-associated white matter hyperintensities 
may evoke cognitive deterioration and subsequently compro-
mise self-reliance and increase healthcare costs. If it could 
be predicted which patients are at risk for developing chronic 
white matter hyperintensities after TAVI, these high-risk 
patients could be protected by using additional procedural 
protective methods, such as cerebral protections devices.
We investigated for the first time to which extent the 
calcification volume of the native aortic valve, aortic arch, 
landing zone and left ventricle measured with cardiac CTA, 
can be used to predict the increase in chronic white matter 
hyperintensities after TAVI, indicating new chronic brain 
infarctions.
Methods
Study population and trial design
The current study is a single center, prospective trial, initi-
ated and managed by the Heart Center of the Amsterdam 
University Medical Center (UMC), a high volume tertiary 
cardiac care and TAVI center. Patients with severe AV steno-
sis planned to undergo TAVI of a native valve were eligible 
for inclusion in the trial. Exclusion criteria for trial participa-
tion were known structural brain disease (including a history 
of stroke or transient ischemic attacks) or presence of an 
MRI contra-indication. The decision for TAVI treatment was 
made by our multidisciplinary TAVI team consisting of a 
cardiac surgeon, an interventional-cardiologist, a radiologist, 
a geriatric internist and a dedicated nurse-practitioner. More-
over, the dedicated multidisciplinary TAVI-team selected 
the access route and the valve size, all according to the most 
recent guidelines [5]. The transfemoral approach was the 
default access option, alternatively, in patients with severe 
peripheral artery disease the transaortic route was used. The 
study protocol was approved by the Institutional Review 
Boards of the Academic Medical Center and all participants 
provided written informed consent. The current study is reg-
istered at the Netherlands Trial Register (NL7495).
Endpoints
The main objectives of the study were to determine the dis-
tribution of calcification volumes  (mm3) using CTA in four 
prespecified sections of the heart and aortic arch of patients 
undergoing TAVI (Fig. 1) and to determine whether an asso-
ciation exists between the prespecified regional calcification 
volumes  (mm3) and the increase in FLAIR-MRI determined 
cerebral white matter hyperintensity volume (Δ% from base-
line mL), 3 months after TAVI. This relative increase (Δ%) 
rather than the actual increase (ΔmL) was chosen since we 
expected large variations in baseline white matter hyperin-
tensity volumes between patients and baseline white mat-
ter hyperintensity volume is known to predict the actual 
increase in volume over time (ΔmL) [9]. Hence, by select-
ing the relative increase (Δ%) we investigated the influence 
of the TAVI-procedure rather than the baseline patient risk. 
The secondary objective was to determine clinical (patient) 
predictors of both the calcification volume  (mm3) and of 
actual increase in new white matter hyperintensities (mL).
Cerebral MRI and cardiac CTA acquisition and image 
analyses
A detailed description of the image acquisition and analy-
ses is provided as supplementary text with correspond-
ing table and figure (Fig. 1; Supplementary text 1 and 
Table 1). In brief, the included patients underwent cerebral 
MRI evaluation of white matter hyperintensities using a 
FLAIR sequence at a 3-T MRI scanner at baseline ( < 24 h 
prior to the TAVI procedure) and 3 months after the TAVI. 
The FLAIR sequence was used because of its sensitiv-
ity to measure white matter hyperintensities, appearing as 
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lesions with increased brightness. White matter hyperin-
tensities were quantified using an automated segmentation 
method. CTA scans were acquired in all patients as part 
of the routine pre-TAVI work-up and used to measure the 
calcification volumes in the selected segments (Fig. 2). In 
these CTA scans, patient-specific cut-off values for cal-
cifications were automatically detected to minimize dif-
ferences in calcification volume measurements between 
patients with different CTA setting [tube voltage (kV)] and 
different contrast delivery protocol. These cut-off values 
were based on the distribution of the amount of pixels with 
pixel-values, corresponding with the primary components 
of the segments (calcifications, contrast material and soft-
tissue) (Fig. 1).
Statistical analysis
Continuous values of patient and MRI characteristics, 
including calcification volumes per segment and white 
matter hyperintensity volumes were tested for normal dis-
tribution and are reported as mean ± SD or median with 
interquartile ranges  (Q1–Q3 25–75th percentile) where 
appropriate. Accordingly, depending on the distribution of 
the data, either the independent t-test or Mann–Whitney 
U test determined differences between groups. Categori-
cal variables are presented as frequencies and percentages, 
differences between groups were tested with Chi-square. 
Moreover, the calcification volumes per segment  (mm3) 
were explored as predictors of the relative increase of white 
Fig. 1  Methodology of calcification segmentation
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matter hyperintensities (Δ%) using linear regression. In a 
secondary analysis, to correct for inter-individual variance in 
intracranial volumes, the white matter hyperintensity volume 
(mL) was normalized for intracranial volume (mL). Moreo-
ver, baseline patient characteristics were explored by linear 
regression as predictors of either the baseline calcification 
volume per segment  (mm3) or the increase of white matter 
hyperintensities (ΔmL). Potential clinical predictors were 
tested in a univariate model, and if p < 0.05, simultaneously 
entered to create a multiple regression model. The results 
of all regression models are reported as beta coefficients 
(B) and standard errors (SEs). All statistical tests were two-
tailed, and a value of p < 0.05 was considered to indicate a 
statistically significant difference. Calculations were gener-
ated using SPSS software (version 25.0 for Windows, SPSS, 
Inc., Chicago, Illinois).
Results
Baseline patient characteristics
Between June 2016 and November 2017, a total of 48 
patients with severe AV stenosis in the work-up for TAVI 
underwent baseline assessment of white matter hyper-
intensity volume. Twelve patients (25%) did not undergo 
Table 1  Baseline patient and 
procedural characteristics
Values are mean ( ± SD), n (%) or median (interquartile range)
VKA vitamin K antagonist, NOAC novel oral anticoagulant
Study population (n = 36)
Demographics
 Age (years) 78.7 ± 4.5
 Female gender 22 (61%)
 Body mass index (kg/m2) 29.8 ± 7.4
Medical history
 Previous myocardial infarction 6 (17%)
 Previous PCI 10 (28%)
 Previous CABG 3 (8%)
 Diabetes mellitus 10 (28%)
 Hypertension 21 (58%)
 Dyslipidemia 6 (17%)
 History of coronary artery disease 14 (39%)
 Atrial fibrillation 16 (44%)
 Glomerular filtration rate < 30 mL/min/1.73 m2 3 (8%)
 NT-proBNP (ng/L) 882 (361–2775)
 New York Heart Association (NYHA) class III or IV 22 (61%)
Risk scores
 EuroSCORE II (%) 1.9 (1.5–3.4)
 STS-PROM mortality (%) 2.8 (1.9–3.7)
Echocardiographic characteristics
 Aortic max gradient (mmHg) 68 ± 24
 Aortic mean gradient (mmHg) 43 ± 17
 Aortic valve area  (cm2) 0.74 ± 0.16
Procedural details
 Transfemoral access 33 (92%)
 Transaortic access 3 (8%)
 Edwards SAPIEN 3 35 (97%)
 Direct flow 1 (3%)
Medication at discharge
 Single antiplatelet therapy 1 (3%)
 Dual antiplatelet therapy 18 (50%)
 Single antiplatelet therapy + anticoagulation therapy (VKA/NOAC) 12 (33%)
 Anticoagulation therapy only (VKA/NOAC) 5 (14%)
 Statin 24 (67%)
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follow-up cerebral MRI 3  months after the procedure 
related to either post-TAVI pacemaker implantation (n = 6) 
or refusal of MRI follow-up (n = 6). Accordingly, the final 
study population included 36 TAVI patients with complete 
MRI follow-up. Baseline demographic and clinical char-
acteristics of the patients are provided in Table 1. Mean 
age was 78.7 ± 4.5 years with the majority (61%) female. 
The Society of Thoracic Surgeons (STS) median score of 
2.8%  (Q1–Q3 1.9–3.7%) indicated this was a low-risk TAVI 
population. Nevertheless, many patients had comorbidi-
ties including diabetes (28%), atrial fibrillation (44%) and 
a history of coronary artery disease (39%). The majority 
of the patients underwent transfemoral TAVI (92%) with a 
balloon-expandable Edwards SAPIEN 3 valve (97%). Fol-
lowing TAVI, 50% of the patients were treated with dual 
antiplatelet therapy (DAPT) and 33% received single anti-
platelet therapy (SAPT) in combination with anticoagu-
lant therapy. Patients not undergoing MRI follow-up had 
a higher median EuroSCORE II (3.4%,  Q1–Q3 2.0–4.6%, 
vs. 1.9%,  Q1–Q3 1.5–3.5%, p = 0.03) and a larger AV area 
(0.91 ± 0.18 cm2 vs. 0.74 ± 0.16  cm2 vs., p = 0.004) prior to 
 TAVI.(Supplementary Table 2).
Cardiac and aortic calcification volumes
Out of the four prespecified segments median calcifi-
cation volumes were the highest in the AV (692  mm3, 
 Q1–Q3 482–1297 mm3) and the aortic arch (633 mm3,  Q1–Q3 
213–1727 mm3). The distribution of the calcification vol-
umes in the AV are displayed in Fig. 3. A CTA example of a 
low versus a high calcification volume of the AV is shown in 
Fig. 4. In multiple regression analysis, AV calcification vol-
umes were larger in patients with a larger (CT-determined) 
annular area, with a 3.8 mm3 (SE 1.2, p = 0.004) increase of 
AV calcification volume per every additional  mm2 of annu-
lar area (Supplemental Table 3). Moreover, patients with a 
higher mean gradient had higher AV calcification volumes, 
with a 15.9 mm3 (SE 4.9, p = 0.003) increase per every 
additional mmHg mean gradient increase. The majority of 
patients with severe AV stenosis (82%) also had some calci-
fications in the left ventricle. These calcifications were gen-
erally located around the mitral valve and had a lower vol-
ume than the AV and arch (164 mm3,  Q1–Q3 19–1332 mm3). 
Finally, 63% of the patients had calcifications in the landing 
zone, with a relatively low calcification volume compared 
with the other segments (16 mm3,  Q1–Q3 0–68 mm3).
Cerebral white matter hyperintensity volume
All patients with severe AV stenosis had white mat-
ter hyperintensities prior to TAVI, with a median vol-
ume of 5.1 mL  (Q1–Q3 2.1–8.9 mL), this was 0.4% of 
the total intracranial volume  (Q1–Q3 0.2–0.7%). The 
volume of baseline white matter hyperintensities varied 
considerably between patients, the distribution is given 
in Fig. 3. Figure 5 shows two patients with few versus 
widespread white matter hyperintensities. Patients with 
versus without pre-existing atrial fibrillation had a more 
than twofold higher baseline white matter hyperintensity 
volume (8.6 mL,  Q1–Q3 4.2–13.9 mL vs. 3.7 mL,  Q1–Q3 
1.4–6.0 mL, p = 0.03). None of the patients experienced 
clinical overt stroke during the follow-up period. Never-
theless, in 26 patients (72%) the white matter hyperinten-
sity volume increased 3 months after TAVI. The median 
Fig. 2  Segments of the heart and aortic arch used for calcification 
volume determination
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increase in these patients was 1.1 mL  (Q1–Q3 0.3–4.6 mL), 
corresponding with a 27% increase from baseline  (Q1–Q3 
7–104%), the distribution of the increase in white matter 
hyperintensity volume is shown in Fig. 6. The calcifica-
tion volume of the AV predicted the relative increase of 
white matter hyperintensity volume at follow-up (Δ%), 
with a 35.2% increase per 100 mm3 of native AV calcifica-
tion volume (SE 8.5, p < 0.001). The relationship between 
AV calcification volume and the increase in white mat-
ter hyperintensities is displayed in Fig. 6. In contrast, the 
calcification volume of the AV was not associated with the 
volume of baseline white matter hyperintensities (B 0.0, 
SE 0.0, p = 0.87). Furthermore, the calcification volume 
in the aortic arch (B 3.0%, SE 3.7, p = 0.42), landing zone 
(B − 31.9%, SE 79.5, p = 0.69) and left ventricle (B − 3.9%, 
SE 6.5, p = 0.55) did not predict the relative increase in 
cerebral white matter hyperintensity volume. There was 
a considerable variation in intracranial volumes between 
patients, with a median volume of 1352  mL  (Q1–Q3 
1205–1468 mL) at baseline. Correction for intracranial 
Fig. 3  Distribution of aortic 
valve calcification volumes and 
white matter hyperintensities in 
patients with severe aortic valve 
stenosis
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volumes resulted in similar outcomes, with the AV cal-
cification volume remaining a significant predictor of the 
relative increase in white matter hyperintensity volume 
(p < 0.001). In multiple regression analysis, no clinical fac-
tors other than the calcification burden of the AV predicted 
the increase of white matter hyperintensity volume (Sup-
plemental Table 4). 
Discussion
Main findings
This is the first study to address the relationship between 
calcification volumes of the heart and aortic arch prior to 
TAVI and chronic brain infarctions following TAVI. The 
main findings were that in patients with severe AV stenosis a 
large variation exists in CTA assessed calcification volumes 
of the AV. Likewise, the variation in baseline white mat-
ter hyperintensity volumes is considerable, with a twofold 
higher volume in patients with history of atrial fibrillation. 
Cerebral white matter hyperintensity volume increased in 
the majority of patients (72%) during follow-up. A higher 
volume of AV calcification volume pre-TAVI was associated 
with a larger increase of white matter hyperintensity vol-
ume during follow-up, indicating chronic brain infarctions. 
Altogether, these findings show the potential for automated 
AV calcium screening as an imaging biomarker to predict 
chronic silent brain infarctions in patients undergoing TAVI.
Whiter matter hyperintensities after TAVI
The findings of the current study emphasize that the TAVI 
procedure induces a chronic cerebral embolic burden in 
an already frail population. In the current low-risk TAVI 
population, 7 out of 10 patients undergoing TAVI had 
an increase in white matter hyperintensity volume, with 
Fig. 4  Cardiac computed tomography angiography (CTA) aortic 
valve calcification volumes
Fig. 5  Fluid-attenuated inver-
sion recovery (FLAIR) cerebral 
white matter hyperintensities
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a median increase of 1.1 mL  (Q1–Q3 0.3–4.6 mL) in the 
course of 3 months. In comparison, the mean white mat-
ter hyperintensity volume increased with the same volume 
(1.1 ± 1.8 mL) in the course of 4 years in a population-based 
study in healthy subjects with a comparable mean age of 
79 years [10]. Further emphasizing the embolic burden in 
a portion of the patients, we found that half of the patients 
had an increase of new white matter hyperintensities < 1 mL, 
whereas the other half had an increase of 2–12 mL. In pop-
ulation based studies, white matter hyperintensities were 
related to impaired neuropsychological functioning across 
all domains including memory, verbal fluency and mental 
slowing [11].
Similar to findings of the current study, a previous study 
found that the calcification volume of the AV, measured with 
the Agatston calcium score, predicted the number of solid 
cerebral emboli during the TAVI procedure measured with 
transcranial Doppler [12]. The highest number of cerebral 
embolizations takes place during the phase of the valve posi-
tioning, indicating that calcifications dislocate during valve 
placement. Similarly, the current results showed that the AV 
volume predicted the relative increase in white matter hyper-
intensity volume, rather than the calcification volume in the 
aortic arch, landing zone and left ventricle. This is despite 
the fact that large sized catheters are approached through 
the aortic arch with substantial calcification volumes in 
almost all patients. This significant role of AV calcifica-
tions in cerebral embolizations during the TAVI procedure 
is underlined by clinical studies indicating that patients with 
a smaller AV area, higher pre-TAVI AV gradient, increased 
aortic arch atheroma and/or severe aortic calcification, all 
indicating a higher calcification burden, are more likely to 
experience early post-procedural cerebrovascular events [1, 
13–16]. Moreover, not the calcification volume itself, but the 
Fig. 6  Cubic spline curve of 
the relationship between aortic 
valve calcification and increase 
in cerebral white matter hyper-
intensities. Distribution of the 
increase in cerebral white mat-
ter hyperintensities 3 months 
after TAVI
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plaque volume in the AV of a lower density than calcifica-
tions (50–130 HU), matching fibrous tissue, was shown to 
be associated with the occurrence of new DW-MRI lesions 
short after TAVI [6]. However, studies in TAVI populations 
did not find a relationship between occurrence of these new 
DW-MRI lesions after TAVI and (long-term) neurocogni-
tive decline [17]. A mismatch between the presence of acute 
ischemic lesions detected with DW-MRI and the absence of 
chronic white matter hyperintensities detected with FLAIR, 
can be applied to identify salvageable brain areas [18]. In 
contrast to acute DW-MRI lesions, there is an association 
between long-term white matter hyperintensities in TAVI 
patients and a clear trend of cognitive decline, indicating 
that not all acute silent infarctions continue to be chronic 
brain infarctions [7]. Accordingly, in contrast to the DW-
MRI study, the findings of the current study highlight the 
relationship between calcification volume in patients with 
AV stenosis and the increased risk of new white matter 
hyperintensities after TAVI, which will potentially induce 
long-term cognitive deterioration.
The risk of atrial fibrillation in TAVI patients
The reported prevalence of pre-existing atrial fibrillation in 
TAVI patients ranges from 16 to 51% [19]. An interesting 
finding of the current study was that patients with a history 
of atrial fibrillation had a more than twofold higher volume 
of baseline white matter hyperintensity volume before TAVI 
compared without pre-existing atrial fibrillation. This find-
ing is in accordance with data from a large population-based 
study [20]. Patients with atrial fibrillation are at heightened 
risk of cognitive decline and dementia, even in the absence 
of a medical history of past stroke [13]. Moreover, compared 
with healthy control subjects, patients with atrial fibrillation 
have a lower cerebral perfusion and impaired cerebrovascu-
lar reactivity indicative of a limited cerebral vascular reserve 
[14]. These findings emphasize the risk of atrial fibrillation 
on cognitive functioning in patients with AV stenosis.
Reduction of new white matter hyperintensities 
after TAVI
Unfortunately, reliable clinical characteristics that predict 
the risk of (silent) brain infarctions after TAVI are lacking 
in the existing literature. We believe the findings from the 
current study, at the background of previous studies, indicate 
that the routinely performed CTA during pre-TAVI work-
up could identify patients at risk for TAVI induced chronic 
silent brain infarctions. Identification of significant ascend-
ing aortic atheroma, using preoperative CT, in patients 
undergoing cardiac surgery, followed by tailored alterna-
tive operative strategies led to a threefold lower stroke rate 
compared with patients who did not undergo aortic atheroma 
identification with CT (p = 0.05) [15]. In a similar way, the 
AV calcification volume, measured with automated algo-
rithms in CTA’s during the pre-TAVI work-up could assess 
the risk of cerebral embolization during TAVI and identify 
patients that could benefit from expensive cerebral protec-
tion devices [16].
Limitations
The current study did not include a control population, that 
did not undergo TAVI. Moreover, the current study included 
a low-risk population, whereas the calcification burden may 
be even higher in intermediate and high-risk populations. 
Subsequently, a higher calcification burden may be associ-
ated with a higher volume of new white matter hyperintensi-
ties after TAVI. Similarly, the current study included only 
balloon-expandable valves, even though self-expandable 
valves have been associated with a higher stroke rate [21]. 
Balloon-expandable valves are implanted rather rapidly, in 
contrast, self-expandable valves are implanted stepwise and 
slowly and allow repositioning before the final implanta-
tion. Therefore, we cannot exclude a relation between the 
calcification volume in the ascending aorta or left ventricular 
outflow trajectory and new white matter hyperintensities in 
patients treated with self-expandable valves. Furthermore, 
were not able to use the commonly used Agatston calcium 
score as this has not been validated in contrast enhanced 
cardiac CTA scans. Non-contrast CT scans of the heart 
were not part of the TAVI work-up. Moreover, white matter 
hyperintensities not only include chronic brain infarctions 
but also regions of small vessel disease. The former is char-
acterized by a rather acute increase of volume, whereas the 
latter is characterized by a slow gradual increase. Therefore, 
we believe that by selecting the relative increase (Δ%) over 
the course of a short period of 3 months as the endpoint, 
the measured outcome mainly detects new infarctions rather 
than small vessel disease. Finally, cognitive functioning tests 
were not performed in the current study and relationships 
between the AV calcification volume, the volume of new 
white matter hyperintensities and cognitive functioning can-
not be confirmed. Even though various studies reported a 
relationship between the increase in white matter hyperin-
tensities and neuropsychological functioning, there is cur-
rently limited evidence reporting an increase in white matter 
hyperintensity volumes is associated with neurocognitive 
impairment [22, 23].
Conclusions
In a low-risk population with severe AV stenosis, all patients 
had valve calcifications prior to TAVI, with a large variation 
in calcification volumes between patients. The majority of the 
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patients (72%) had new cerebral white matter hyperintensities 
3 months after TAVI, with a median increase of 27%. A larger 
calcification volume in the AV, but not in the aortic wall, land-
ing zone and left ventricle prior to TAVI was associated with 
a higher increase in cerebral white matter hyperintensity vol-
ume after TAVI, indicating new chronic brain infarctions.
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